Prospective phase II study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes

Clinical Cancer Research

Volumn 19, Issue 12, 2013, Pages 3297-3308

  Filì, Carla ^a   Malagola, Michele ^a   Follo, Matilde Y ^b   Finelli, Carlo ^b   Iacobucci, Ilaria ^b   Martinelli, Giovanni ^b   Cattina, Federica ^a   Clissa, Cristina ^b   Candoni, Anna ^c   Fanin, Renato ^c   Gobbi, Marco ^d   Bocchia, Monica ^e   Defina, Marzia ^e   Spedini, Pierangelo ^f   Skert, Cristina ^a   Manzoli, Lucia ^b   Cocco, Lucio ^b   Russo, Domenico ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY HOSPITAL OF UDINE   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e UNIVERSITY OF SIENA   (Italy)

^f CREMONA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; AZACITIDINE; CYCLOSPORIN A; DANAZOL; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PHOSPHOLIPASE C BETA1;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BLEEDING; BLOOD TOXICITY; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DNA METHYLATION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; INJECTION SITE ERYTHEMA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROMOTER REGION; PROSPECTIVE STUDY; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REMISSION; RESPIRATORY DISTRESS; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; AZACITIDINE; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOLOGIC TESTS; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PHOSPHOLIPASE C BETA; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; TREATMENT OUTCOME; WNT1 PROTEIN;

EID: 84879471312     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3540     Document Type: Article

References (42)

1. Issa JP. Epigenetic changes in the myelodysplastic syndrome. Hematol Oncol Clin North Am 2010;24:317-30.
2. Taby R, Issa JP. Cancer epigenetics. CA Cancer J Clin 2010;60: 376-92.
3. Nolte F, Hofmann WK. Molecular mechanisms involved in the progression of myelodysplastic syndrome. Future Oncol 2010;6:44555.
4. Garcia-Manero G, Fenaux P. Hypomethylating agents and other novel strategies in myelodysplastic syndromes. J Clin Oncol 2011;29: 516-23.
5. Jain NE, Rossi A, Garcia-Manero G. Epigenetic therapy of leukaemia: an update. Int J Biochem Cell Biol 2009;41:72-80.
6. Garcia Manero G. Treatment of higher-risk myelodysplastic syndrome. Semin Oncol 2011;38:673-81.
7. Quintas-Cardama A, Santos FP, Garcia-Manero G. Therapy with azanucleosides for myelodysplastic syndromes. Nat Rev Clin Oncol 2010;7:433-44.
8. Follo MY, Faenza I, Fiume R, Ramazzotti G, McCubrey JA, Martelli AM, et al. Revisiting nuclear phospholipase C signalling in MDS. Adv Enzyme Regul 2012;52:2-6.
9. Cocco L, Follo MY, Faenza I, Fiume R, Ramazzotti G, Weber G, et al. Physiology and pathology of nuclear phospholipaseCb1. Adv Enzyme Regul 2011;51:2-12.
10. Follo MY, Finelli C, Bosi C, Martinelli G, Mongiorgi S, Baccarani M, et al. PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes. Leukemia 2008;22: 198-200.
11. Follo MY, Finelli C, Mongiorgi S, Clissa C, Bosi C, Testoni N, et al. Reduction of phosphoinositide-phospholipase C beta 1 methylation predicts the responsiveness to azacitidine in high-risk MDS. Proc Natl Acad Sci U S A 2009;106:16811-6.
12. Follo MY, Finelli C, Mongiorgi S, Clissa C, Chiarini F, Ramazzotti G, et al. Synergistic induction of PI-PLCbeta1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes. Leukemia 2011;25:271-80.
13. Martelli AM, Fiume R, Faenza I, Tabellini G, Evangelista C, Bortul R, et al. Nuclear phosphoinositide specific phospholipase C (PI-PLC)-beta 1: a central intermediary in nuclear lipid-dependent signal transduction. Histol Histopathol 2005;20:1251-60.
14. Faenza I, Billi AM, Follo MY, Fiume R, Martelli AM, Cocco L, et al. Nuclear phospholipase C signaling through type 1 IGF receptor and its involvement in cell growth and differentiation. Anticancer Res 2005;25: 2039-41.
15. Ramazzotti G, Faenza I, Fiume R, Matteucci A, Piazzi M, Follo MY, et al. The physiology and pathology of inositide signaling in the nucleus. J Cell Physiol 2011;226:14-20.
16. FolloMY, Mongiorgi S, Finelli C, Clissa C, Ramazzotti G, Fiume R, et al. Nuclear inositide signaling in myelodysplastic syndromes. J Cell Biochem 2010;109:1065-71.
17. Follo MY, Finelli C, Clissa C, Mongiorgi S, Bosi C, Martinelli G, et al. Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia. J Clin Oncol 2009;27:782-90.
18. Follo MY, Russo D, Finelli C, Mongiorgi S, Clissa C, Fili C, et al. Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment. Leukemia 2012;26:943-50.
19. Follo MY, Mongiorgi S, Clissa C, Paolini S, Martinelli G, Martelli AM, et al. Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients. Leukemia 2012;26: 2474-82.
20. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223-32.
21. Fenaux P, Ades L. Review of azacitidine trials in intermediate-2-and high-risk myelodysplastic syndromes. Leuk Res 2009;33(Suppl 2): S7-11.
22. Hellstr€om-Lindberg E, Malcovati L. Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes. Semin Hematol 2008;45:14-22.
23. Oliva EN, Finelli C, Santini V, Poloni A, Liso V, Cilloni D, et al. Quality of life and physicians' perception in myelodysplastic syndromes. Am J Blood Res 2012;2:136-47.
24. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002;20:2429-40.
25. Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006;24:3895-903.
26. Lyons RM, Cosgriff TM, Modi SS, Gersh RH, Hainsworth JD, Cohn AL, et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 2009;27:1850-56.
27. Musto P, Maurillo L, Spagnoli A, Gozzini A, Rivellini F, Lunghi M, et al. Azacitidine for the treatment of lower risk myelodysplastic syndromes: a retrospective study of 74 patients enrolled in an Italian named patient program. Cancer 2010;116:1485-94.
28. Cheson BD, Greenberg PL, Bennet JM, Lowenberg B, Wijermans P, Nimer S, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419-25.
29. Follo MY, Bosi C, Finelli C, Fiume R, Faenza I, Ramazzotti G, et al. Realtime PCR as a tool for quantitative analysis of PI-PLCbeta1 gene expression in myelodysplastic syndrome. Int J Mol Med 2006;18: 267-71.
30. Iacobucci I, Storlazzi CT, Cilloni D, Lonetti A, Ottaviani E, Soverini S, et al. Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCRABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). Blood 2009;114:2159-67.
31. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 2009;114:937-51.
32. Fili{dotless} C, Gobbi M, Martinelli G, Finelli C, Iacobucci I, Ottaviani E, et al. Azacitidine low-dose schedule in symptomatic low-risk (IPSS:0-1) myelodysplastic patients. Clin Biol Eff Haematol 2012;95(Suppl 3): S32-33.
33. Fil{dotless} C, Finelli C, Gobbi M, Martinelli G, Iacobucci I, Ottaviani E, et al. Azacitidine low-dose schedule in low-risk myelodysplastic syndromes. Preliminary results of a multicenter phase II study [abstract]. In: Proceedings of the 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; Orlando, FL: Orange County Convention Center; 2011. p. 116. Abstract nr 4029.
34. Fil{dotless} C, Finelli C, Gobbi M, Martinelli G, Iacobucci I, Ottaviani E, et al. Clinical results of a multicenter phase II study. Leuk Res 2011;35 (Suppl 1):S84-85.
35. Jadersten M, Hellstrom-Lindberg E. Myelodysplastic syndromes: biology and treatment. J Intern Med 2009;265:307-28.
36. Komrokji RS, Sekeres MA, List AF. Management of lower-risk myelodysplastic syndrome: the art and evidence. Curr Hematol Malig Rep 2011;6:145-53.
37. Novotna B, Neuwirtova R, Siskova M, Bagryantseva Y. DNA instability in low-risk myelodysplastic syndromes: refractory anemia with or without ring sideroblasts. Hum Mol Genet 2008;17: 2144-9.
38. Tobiasson M, Brandefors L, Dybedal I, Garelius H, Grovdal M, Dufva IH, et al. Evaluation of Azacitidine in transfusion-dependent, epo-refractory patients with lower-risk myelodysplastic syndrome [abstract]. In: Proceedings of the 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, CA: San Diego Convention Center; 2011. p. 118. Abstract nr 3798.
39. Morris JF, Rauscher FJ III, Davis B, Klemsz M, Xu D, Tenen D, et al. The myeloid zinc finger gene, MZF-1, regulates the CD34 promoter in vitro. Blood 1995;86:3640-7.
40. Mohamedali A, Gaken J, Twine NA, Ingram W, Westwood N, Lea N, et al. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood 2007;110:3365-73.
41. Gondek LP, Tiu R, O'Keefe CL, Sekeres MA, Theil KS, Maciejewski JP. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS,MDS/MPD, and MDS-derived AML. Blood 2008;111:1534-42.
42. Yi JH, Huh J, Kim HJ, Kim S, Kim SH, Kim KH, et al. Genome-wide single-nucleotide polymorphism array-based karyotyping in myelodysplastic syndrome and chronic myelomonocytic leukemia and its impact on treatment outcomes following decitabine treatment. Ann Hematol 2012:1635-7.